Phase 1 Protocol for phase 1 HIV clinical study

This is a Pilot Study (Phase I/II) testing the immunologic activity and safety of AGS-004, an autologous HIV immunotherapeutic, in HIV-infected adults on HAART.

Study Design: Patients that are successfully treated with highly active anti-retroviral therapy (HAART) with no measurable viral load AND have a cryopreserved infectious plasma sample that was drawn immediately prior to initiation of HAART will be administered 4 monthly doses of the Arcelis product.

• biomaterial type
• HIV antigen,
• blood plasma

created over 16 years ago (2 March 2009)    last modified over 13 years ago (20 August 2012)   [ RDF ]   [ RelFinder ]